CHEK1 and B-cell non-Hodgkin lymphoma: Tumor cells deficient in Fanconi anemia pathway are hypersensitive to Chk1 inhibition [18] and Chk1 inhibitors are effective against Myc-driven malignancies, such as certain B-cell lymphomas and some breast and lung cancers [19, 20].